78,984 Shares in MediWound Ltd. (NASDAQ:MDWD) Acquired by Silverberg Bernstein Capital Management LLC

Silverberg Bernstein Capital Management LLC purchased a new stake in MediWound Ltd. (NASDAQ:MDWD) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 78,984 shares of the biopharmaceutical company’s stock, valued at approximately $803,000. MediWound accounts for 0.8% of Silverberg Bernstein Capital Management LLC’s portfolio, making the stock its 29th largest holding. Silverberg Bernstein Capital Management LLC owned about 0.86% of MediWound as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. bought a new stake in shares of MediWound in the 4th quarter worth about $57,000. BlackRock Inc. increased its holdings in shares of MediWound by 122.6% during the second quarter. BlackRock Inc. now owns 15,238 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 8,392 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of MediWound by 3.8% in the second quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after acquiring an additional 17,600 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. acquired a new position in shares of MediWound in the 3rd quarter worth approximately $917,000. Finally, Wells Fargo & Company MN grew its position in MediWound by 16.0% during the 2nd quarter. Wells Fargo & Company MN now owns 112,727 shares of the biopharmaceutical company’s stock worth $1,202,000 after acquiring an additional 15,535 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. StockNews.com upgraded MediWound from a “sell” rating to a “hold” rating in a research report on Friday, March 22nd. HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of MediWound in a research report on Friday, March 22nd.

MediWound Stock Down 1.7 %

MediWound stock opened at $15.56 on Wednesday. The stock has a market cap of $147.66 million, a price-to-earnings ratio of -20.21 and a beta of 0.94. MediWound Ltd. has a 12-month low of $7.10 and a 12-month high of $17.25. The business’s 50-day simple moving average is $13.95 and its 200 day simple moving average is $11.01.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.